Kuros Biosciences AG
CSBTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $63,480 | $43,711 | $31,844 | $20,698 |
| % Growth | 45.2% | 37.3% | 53.9% | – |
| Cost of Goods Sold | $7,148 | $10,047 | $3,477 | $3,274 |
| Gross Profit | $56,332 | $33,664 | $28,367 | $17,424 |
| % Margin | 88.7% | 77% | 89.1% | 84.2% |
| R&D Expenses | $4,305 | $3,421 | $3,563 | $3,308 |
| G&A Expenses | $11,136 | -$1,907 | $6,984 | $4,690 |
| SG&A Expenses | $48,530 | $15,780 | $25,477 | $18,363 |
| Sales & Mktg Exp. | $37,394 | $17,687 | $18,493 | $13,996 |
| Other Operating Expenses | -$6 | $18,899 | -$114 | $0 |
| Operating Expenses | $52,829 | $38,100 | $28,926 | $21,671 |
| Operating Income | $3,503 | -$4,436 | -$559 | -$8,663 |
| % Margin | 5.5% | -10.1% | -1.8% | -41.9% |
| Other Income/Exp. Net | -$3,366 | -$6 | $1,655 | $196 |
| Pre-Tax Income | $137 | -$4,442 | $1,096 | -$8,467 |
| Tax Expense | $2,173 | -$937 | $1,307 | $208 |
| Net Income | -$2,013 | -$3,505 | -$211 | -$8,675 |
| % Margin | -3.2% | -8% | -0.7% | -41.9% |
| EPS | -0.051 | -0.094 | -0.006 | -0.24 |
| % Growth | 46.3% | -1,552.6% | 97.6% | – |
| EPS Diluted | -0.051 | -0.094 | -0.006 | -0.24 |
| Weighted Avg Shares Out | 39,805 | 37,199 | 36,890 | 36,604 |
| Weighted Avg Shares Out Dil | 40,260 | 37,199 | 36,890 | 36,604 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$4,015 | $4,178 | $3,089 |
| Interest Expense | $3,366 | -$719 | $868 | $2,892 |
| Depreciation & Amortization | $975 | $1,682 | $954 | $1,035 |
| EBITDA | $4,478 | -$956 | $395 | -$3,093 |
| % Margin | 7.1% | -2.2% | 1.2% | -14.9% |